Inclusion Criteria:

• Diagnosis of Rheumatoid Arthritis
• Current treatment with methotrexate and on a stabl dose between 7.5 mg and 25 mg weekly for at least the past 8 weeks prior to randomization
• Current treatment with either etanercept or adalimumab for at least 3 months prior to randomization
• Current treatment with prednisone or equivalent corticosteroid at stable dose of no more than 10 mg daily for more than 28 days prior to randomization
• Agree to use appropriate form of contraception. More information on this criterion can be found in the protocol.

Exclusion Criteria:

• Diagnosis of another autoimmune disease likely to require immunosuppression. More information on this criterion can be found in the protocol.
• Failing treatment with etanercept if previously treated with adalimumab
• Failing treatment with adalimumab if previously treated with etanercept
• Intraarticular injection within 4 weeks prior to randomization
• Concomitant use of DMARDs other than methotrexate within 4 weeks prior to randomization
• Concurrent use of any biologic agent other than atanercept or adalimumab
• Concomitatn immunosuppressive therapy other than methotrexate, NSAIDS, or corticosteroids. More information on this criterion can be found in the protocol.
• Presence of open leg ulcers
• Chronic or persistent infection that may be worsened by immunosuppressive treatment. More information on this criterion can be found in the protocol.
• Active infection or severe infections requiring hospitalization or treatment with intravenous antibiotics, antivirals, or antifungals within 30 days prior to randomization
• History of positive PPD or chest x-ray findings indicative of prior TB infection
• Any medical condition or treatment that, in the opinion of the investigator, would put the subject at risk by participation in the study
• History of malignancy. More information on this criterion can be found in the protocol.
• Certain abnormal laboratory values. More information on this criterion can be found in the protocol.
• Investigational biological or chemical agents within 4 weeks prior to randomization
• History of drug or alcohol abuse
• Treatment with natalizumab, rituximab, or another B-cell depleting therapy within a year prior to randomization
• Treatment with infliximab, abatacept, or tocilizumab within 3 months prior to randomization
• Known allergy or hypersensitivity to study products
• Any psychiatric disorder that prevents the participant from providing informed consent
• Inability to follow protocol instructions
• Pregnant or breastfeeding